Your browser is no longer supported. Please, upgrade your browser.
Settings
PBYI Puma Biotechnology, Inc. daily Stock Chart
PBYI [NASD]
Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-8.16 Insider Own11.60% Shs Outstand34.17M Perf Week4.35%
Market Cap1.31B Forward P/E- EPS next Y-7.18 Insider Trans-0.52% Shs Float31.67M Perf Month18.91%
Income-265.10M PEG- EPS next Q-1.92 Inst Own97.00% Short Float17.93% Perf Quarter-9.76%
Sales- P/S- EPS this Y-57.50% Inst Trans18.35% Short Ratio7.97 Perf Half Y-23.44%
Book/sh2.80 P/B13.70 EPS next Y11.60% ROA-141.40% Target Price86.33 Perf Year-17.70%
Cash/sh3.19 P/C12.03 EPS next 5Y- ROE-180.00% 52W Range19.74 - 73.27 Perf YTD24.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.66% Beta0.43
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low94.28% ATR2.20
Employees156 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)60.01 Volatility6.34% 6.29%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.20% Profit Margin- Rel Volume1.54 Prev Close40.25
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 AMC Payout- Avg Volume712.93K Price38.35
Recom1.90 SMA2011.05% SMA5011.34% SMA200-8.16% Volume1,099,007 Change-4.72%
Sep-22-16Reiterated Credit Suisse Outperform $54 → $111
Sep-21-16Upgrade Stifel Hold → Buy $61 → $88
Mar-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $103 → $36
Jan-21-16Initiated Credit Suisse Outperform
Dec-14-15Upgrade Citigroup Neutral → Buy
Sep-03-15Initiated Citigroup Neutral
Aug-27-15Initiated JP Morgan Overweight $122
Jan-23-15Initiated RBC Capital Mkts Outperform $282
Aug-19-14Resumed Stifel Hold
Jul-23-14Reiterated UBS Buy $125 → $325
Dec-19-13Reiterated UBS Buy $61 → $125
Dec-19-13Downgrade Stifel Buy → Hold
Jul-22-13Reiterated Stifel Buy $42 → $64
Jun-03-13Reiterated UBS Buy $35 → $49
Mar-25-13Reiterated Stifel Buy $32 → $42
Mar-20-13Reiterated UBS Buy $27 → $35
Feb-14-17 04:15PM  Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference Business Wire
Feb-08-17 04:15PM  Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Business Wire +10.04%
Feb-03-17 09:19AM  Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
Jan-09-17 06:07PM  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
04:55PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI Business Wire
Jan-06-17 02:13PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
08:15AM  Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients Business Wire
Jan-05-17 01:04PM  PUMA BIOTECHNOLOGY, INC. Financials
Jan-03-17 04:15PM  Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Business Wire
Dec-19-16 04:27PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
04:15PM  Puma Biotechnology to Move Stock Exchange Listing to Nasdaq Business Wire
Dec-08-16 12:38PM  Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect -8.42%
08:46AM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
08:35AM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Business Wire
Dec-07-16 06:21PM  Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Business Wire
06:07PM  Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Business Wire
07:00AM  Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
Dec-06-16 06:44PM  CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States Business Wire
Nov-30-16 09:33AM  Why Did Puma Biotechnology Dilute Shareholders? at Motley Fool
Nov-28-16 02:11PM  Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 -5.31%
Nov-22-16 08:12AM  Shareholder Dilution: What Investors Need to Know at Motley Fool
Nov-19-16 10:15AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Nov-15-16 03:57PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Puma Biotechnology, Inc. and Advises Investors with Losses to Contact the Firm Business Wire +7.36%
03:11PM  Heres Why The Puma Biotechnology Inc (PBYI) Pullback Might Be A Buy-In Opportunity at Insider Monkey
03:10PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc. (PBYI) PR Newswire
01:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI PR Newswire
Nov-14-16 07:16PM  Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS) Business Wire -20.44%
05:36PM  What Caused Puma Biotechnology's Shares to Tumble 20.5% Today at Motley Fool
04:37PM  Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone
01:13PM  Puma Biotechnology falls more than 20% at CNBC
11:25AM  Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug
Nov-11-16 10:07PM  Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI PR Newswire
Nov-10-16 07:50AM  Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus
Nov-09-16 05:29PM  Puma Biotech reports 3Q loss +16.25%
05:24PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:15PM  Puma Biotechnology Reports Third Quarter 2016 Financial Results Business Wire
04:11PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report
Nov-03-16 06:24PM  Puma Biotechnology (PBYI) Q3 Earnings: What's in Store? -9.31%
Oct-31-16 04:15PM  Puma Biotechnology to Present at Credit Suisse Healthcare Conference Business Wire
11:38AM  Lifshitz & Miller Law Firm Announces Investigation of Electronics for Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., and TG Therapeutics, Inc. PR Newswire
Oct-28-16 10:07PM  PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. PBYI Business Wire
Oct-25-16 11:45AM  Puma Biotechnology Closes $172 Million Public Offering of Common Stock Business Wire
Oct-23-16 10:15AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Oct-21-16 05:04PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
12:34PM  Puma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program
08:31AM  Puma Biotechnology Announces Underwriters Full Exercise of Option to Purchase Additional Shares Business Wire
Oct-20-16 08:40AM  Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
04:43AM  Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR) at Insider Monkey
Oct-19-16 11:18PM  Puma Biotechnology Prices Public Offering of Common Stock Business Wire -18.90%
03:43PM  Puma Biotech Gears Up for Secondary Offering
01:01PM  Why Puma Biotechnology Inc. Sold Lower Today at Motley Fool
09:07AM  Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More at Insider Monkey
Oct-18-16 05:53PM  Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering
04:36PM  Puma Biotech shares slide on secondary stock offering at MarketWatch
04:15PM  Puma Biotechnology Announces Proposed Public Offering of Common Stock Business Wire
Oct-17-16 06:04AM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
Oct-14-16 10:07PM  PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. PBYI Business Wire
Oct-12-16 02:52PM  Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion to Dismiss in Securities Class Action Business Wire
Oct-11-16 11:30AM  Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company's Top Executives PR Newswire
Oct-10-16 10:32AM  Johnson & Weaver, LLP Initiates Investigations of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. and Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors to Contact the Firm Regarding Their Legal Ri PR Newswire
Oct-04-16 10:15AM  Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) against Directors announced by Shareholders Foundation GlobeNewswire
Sep-30-16 09:13AM  5 Top Performing Stocks of the Best ETF of Q3
09:10AM  SEC Issues Charges Over Biotech Insider Activity
07:00AM  Biotech Stock Mailbag: Dynavax, Puma, Ariad
Sep-29-16 04:05PM  SEC charges former Puma Biotech employee with insider trading Reuters
Sep-27-16 11:49AM  Momentum Carries Lululemon Lower, Pushes Biotech Names Higher at Forbes
Sep-25-16 10:45AM  6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside at 24/7 Wall St.
10:20AM  Could Puma Biotech Double After This FDA Approval? at 24/7 Wall St.
Sep-22-16 04:31PM  Puma Races To Eight-Month High On Breast Cancer Drug Success
03:42PM  Greater Expectations For Puma Technology Boost Credit Suisse Target Price To $111
11:50AM  Why Key Analyst Sees Puma Biotech Practically Doubling at 24/7 Wall St.
10:56AM  Puma Biotechnology Shares Leap Forward
10:11AM  Puma Biotechnology: That's Some Target Increase!!! at Barrons.com
09:05AM  Top Analyst Upgrades and Downgrades: Alibaba, Amazon, Bed Beth & Beyond, Puma Biotechnology, SeaWorld and More at 24/7 Wall St.
Sep-21-16 03:38PM  4 health-care stocks to watch at MarketWatch
11:01AM  3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions at Motley Fool
10:51AM  Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
07:22AM  Puma Biotech. upgraded by Stifel
05:45AM  Puma Biotechnology (PBYI) Shares March Higher, Can It Continue?
Sep-20-16 04:52PM  Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm +10.53%
03:01PM  Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy at Motley Fool
02:27PM  Why Puma Biotechnology Inc Roared Higher Today at Motley Fool
01:49PM  Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
01:13PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
12:29PM  Heres Why These Five Stocks Are on the Move Today at Insider Monkey
11:35AM  Why Puma Biotechnology (PBYI) Stock Is Surging Today
11:15AM  Puma Biotech Rises on Key FDA Approval at 24/7 Wall St.
09:51AM  Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA at Barrons.com
08:01AM  Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire
Sep-19-16 03:00PM  After Losing Medivation, Who Is Gilead Going After Next? at Forbes
Sep-13-16 03:14PM  Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016
10:13AM  Puma Biotechnology (PBYI): Moving Average Crossover Alert
Sep-06-16 04:00PM  3 Hottest Cancer Biotech Acquisition Targets After Medivation at Forbes
Aug-23-16 12:07PM  4 Biotech Stock Charts You Must See
09:37AM  Puma (PBYI) Neratinib's Application Validated in EU, Stock Up
Aug-22-16 04:20PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events +9.10%
02:57PM  After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next at Barrons.com
08:05AM  Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe Business Wire
Aug-19-16 09:30AM  The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
Aug-18-16 02:39PM  4 Biggest Winners from This Earnings Season
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) and PB272 (neratinib (intravenous) that are in Phase-III and Phase-II clinical trials for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, and HER2 mutation-positive solid tumors. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHARNAS ROBERTFeb 01Sale31.833,00895,75526,453Feb 02 05:43 PM
Lo StevenChief Commercial OfficerJan 20Sale33.242,29076,10829,210Jan 24 05:56 PM
EYLER CHARLES RSEE REMARKSJan 20Sale33.2482027,2539,680Jan 24 05:53 PM
CHARNAS ROBERTJan 20Sale33.242,29376,20829,407Jan 24 05:52 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVJan 20Sale33.242,29376,20829,237Jan 24 05:51 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 20Sale33.2410,202339,0644,179,798Jan 24 05:49 PM